FDA-cleared profile

Lumify Diagnostic Ultrasound System

Philips Ultrasound · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.

Clinical role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
Images and patients
Ultrasound · Multi-region
Key limitation
Keep in mind: Auto EF Quantification feature will be available on version 5.0 (Android) of Lumify Diagnostic Ultrasound System. Auto EF is a new Artificial Intelligence (AI) feature available on the S4-1 transducer in the Cardiac Preset on the Lumify application based on the LVivo EF algorithm. It provides automated assessment of the LV EF supporting evaluation from only apical four chamber (A4CH) view.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Multi-region Input: The Philips Lumify Diagnostic Ultrasound System (Lumify) is a mobile, durable, and reusable, software-controlled medical device, which is intended to acquire high-resolution ultrasound data and to display the data in B (2D), Pulsed Wave Doppler, Color Doppler, Combined (B+ Color), and M modes.
  • Who uses it?Intended users: healthcare professionals
  • What does the software produce?Output: The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).
  • What is its most important limitation?Key limitation: Auto EF Quantification feature will be available on version 5.0 (Android) of Lumify Diagnostic Ultrasound System. Auto EF is a new Artificial Intelligence (AI) feature available on the S4-1 transducer in the Cardiac Preset on the Lumify application based on the LVivo EF algorithm. It provides automated assessment of the LV EF supporting evaluation from only apical four chamber (A4CH) view.

Clinical takeaway. Clinical role: Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.

Evidence takeaway. Evidence from the reviewed source record: K232500 reports software, system, and feature validation supporting Auto EF and the specified Android configuration; exact feature availability differs across Android and iOS releases.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
The Philips Lumify Diagnostic Ultrasound System (Lumify) is a mobile, durable, and reusable, software-controlled medical device, which is intended to acquire high-resolution ultrasound data and to display the data in B (2D), Pulsed Wave Doppler, Color Doppler, Combined (B+ Color), and M modes.
  • Exact FDA submission
  • Checked 2026-09-19

This replaces the dossier's live/imported data wording with the packet's direct acquisition and display description.

Output and clinician action
The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).
  • Exact FDA submission
  • Checked 2026-09-19

The packet directly states the Auto EF outputs and does not state the dossier's reports output.

Care setting
Hospitals, clinics, offices, and point-of-care environments within the device's cleared applications.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
healthcare professionals
  • Exact FDA submission
  • Checked 2026-09-19

The packet states use in environments where healthcare is provided by healthcare professionals and does not establish the dossier's specific role list.

Limitations
Auto EF Quantification feature will be available on version 5.0 (Android) of Lumify Diagnostic Ultrasound System. Auto EF is a new Artificial Intelligence (AI) feature available on the S4-1 transducer in the Cardiac Preset on the Lumify application based on the LVivo EF algorithm. It provides automated assessment of the LV EF supporting evaluation from only apical four chamber (A4CH) view.
  • Exact FDA submission
  • Checked 2026-09-19

The packet states the Android-version, transducer, and A4CH scope; it does not state the dossier's general image-quality and release-variation limitation.

Evidence summary
K232500 reports software, system, and feature validation supporting Auto EF and the specified Android configuration; exact feature availability differs across Android and iOS releases.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K232500 reports software, system, and feature validation supporting Auto EF and the specified Android configuration; exact feature availability differs across Android and iOS releases.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K232500 FDA performance package for Lumify Diagnostic Ultrasound System

  • DesignManufacturer ultrasound-system and Auto EF verification
  • PopulationSupported broad ultrasound applications and adult cardiac ejection-fraction workflows
  • Scopeexact submission
  • Tested versionLumify Android release with Auto EF
  • IndependenceSponsor or vendor study

K232500

Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
1 reviewed FDA recall record in the 2026-09-02 openFDA snapshot natively identify K232500. Confirm affected model, version, unit, correction, and current manufacturer instructions. FDA recall Z-0883-2026 affects specified Lumify models used with Apple devices running iOS 18. Compatibility problems could prevent live imaging. FDA lists the recall as open and classified.
  • FDA source
  • Exact product version
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-0883-2026

Open, Classified

2025-12-04

Exact Lumify product and native submission match; the issue is limited to specified models and the affected iOS path, while Android and Lightning-port conditions differ.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: The Philips Lumify Diagnostic Ultrasound System (Lumify) is a mobile, durable, and reusable, software-controlled medical device, which is intended to acquire high-resolution ultrasound data and to display the data in B (2D), Pulsed Wave Doppler, Color Doppler, Combined (B+ Color), and M modes.

    Scope: Exact FDA submission. This replaces the dossier's live/imported data wording with the packet's direct acquisition and display description.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K232500: Lumify Diagnostic Ultrasound System

  2. Routing

    Source context, not route validation: Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K232500: Lumify Diagnostic Ultrasound System · Philips Lumify handheld ultrasound · Philips Lumify app and connectivity

  3. AI processing

    Source context, not route validation: Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K232500: Lumify Diagnostic Ultrasound System · Philips Lumify handheld ultrasound · Philips Lumify app and connectivity

  4. Returned objects

    Source context, not route validation: The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).

    Scope: Exact FDA submission. The packet directly states the Auto EF outputs and does not state the dossier's reports output.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K232500: Lumify Diagnostic Ultrasound System

  5. Viewer/worklist/report

    Unresolved route: The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).

    Scope: Exact FDA submission. The packet directly states the Auto EF outputs and does not state the dossier's reports output.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K232500: Lumify Diagnostic Ultrasound System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.

Training
Only qualified physicians, sonographers, and other trained ultrasound professionals. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: AI-assisted measurements and views do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K232500 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AI-assisted measurements and views do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: AI-assisted measurements and views do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232500
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-10-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 3 history items

Source ledger

  1. FDA K232500: Lumify Diagnostic Ultrasound System

    U.S. Food and Drug Administration - Published 2023-10-26 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, evidenceSummary, intendedUsers, input, output, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-0883-2026: Lumify Diagnostic Ultrasound System models : 795005, 795161, 989605449841,

    U.S. Food and Drug Administration - Published 2025-12-04 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. Philips Lumify handheld ultrasound

    Philips - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  9. Philips Lumify app and connectivity

    Philips - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  10. Philips: Responsible Disclosure Statement

    Philips - Accessed 2026-10-26

    Scope: security

Research history

  1. K232500 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251322

Venue; Venue Go; Venue Fit; Venue Sprint

GE Medical Systems Ultrasound and Primary care Diagnostics

Authorized purpose: Venue, Venue Go, Venue Fit, and Venue Sprint are general-purpose point-of-care ultrasound systems for trained users across broad adult, pediatric, and neonatal applications, with release-specific AI guidance and measurement functions.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-07-25
FDA-cleared K250087

Vscan Air

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: Vscan Air is a wireless handheld point-of-care ultrasound system for broad adult, pediatric, and neonatal applications. K250087 adds deep-learning automatic bladder-volume measurement and compatibility with separately cleared Caption Guidance and AutoEF functions.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-05-01
FDA-cleared K242005

Versana Premier; Versana Premier Lotus; LOGIQ F

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: Versana Premier, Versana Premier Lotus, and LOGIQ F are general-purpose diagnostic ultrasound systems for broad hospital and clinic applications; K242005 adds transesophageal use, reporting and guidance tools, measurements, remote service functions, and other release-specific workflow features.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2024-10-02
FDA-cleared K233826

Kosmos

EchoNous, Inc.

Kosmos acquires, processes, displays, measures, and stores ultrasound with synchronized ECG and digital auscultation across cardiac, lung, abdominal, vascular, musculoskeletal, and interventional applications. Adult-only Auto EF and AI FAST are adjunct functions.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2024-08-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history